Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.66 |
| ▸ | CTSS | P25774 | 9/20 | 0.66 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 4/20 | 0.44 |
| ▸ | CTSB | P07858 | 3/20 | 0.44 |
| ▸ | CTSH | P09668 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13592483 | 0.83 | CTSK (0.53) | CTSKCTSSCTSLCTSBCTSH | |
| SCHEMBL24298421 | 0.83 | CTSK (0.64) | CTSKCTSSAAK1CTSLCTSB | |
| SCHEMBL952034 | 0.83 | CTSK (0.64) | CTSKCTSSAAK1CTSLCTSB | |
| SCHEMBL952036 | 0.83 | CTSK (0.64) | CTSKCTSSAAK1CTSLCTSB | |
| SCHEMBL7857628 | 0.83 | CTSK (0.61) | CTSKCTSSAAK1CTSLCTSB | |
| SCHEMBL27978270 | 0.83 | CTSK (0.61) | CTSKCTSSAAK1CTSLCTSB | |
| SCHEMBL29414317 | 0.82 | CTSK (0.60) | CTSKCTSSAAK1CTSLHDAC4 | |
| Water SCHEMBL266526 | 0.81 | CTSK (0.73) | CTSKCTSSAAK1CTSLCTSB | |
| Water SCHEMBL15646368 | 0.81 | CTSK (0.73) | CTSKCTSSAAK1CTSLCTSB | |
| SCHEMBL14272583 | 0.81 | CTSK (0.58) | CTSKCTSSAAK1CTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718691-B2 | Compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718691-B2 | Compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION (US) | 2010-05-18 | — | — | US | disclosed |
| US-7635694-B2 | For treating hepatitis C and related disorders such as HIV, AIDS (Acquired Immune Deficiency Syndrome) | SCHERING CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| US-7423058-B2 | Inhibitors of hepatitis C virus NS3 protease | SCHERING CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| US-7423058-B2 | Inhibitors of hepatitis C virus NS3 protease | SCHERING CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| US-20070142301-A1 | Novel inhibitors of Hepatitis C virus NS3 protease | MERCK SHARP & DOHME CORP. | 2007-06-21 | — | — | US | disclosed |
| US-20070049536-A1 | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049536-A1 | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease | SCHERING CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070021351-A1 | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor | SCHERING CORPORATION | 2007-01-25 | — | — | US | disclosed |
| US-20070021351-A1 | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor | SCHERING CORPORATION | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049536-A1 | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease | SERPINB1, HAVCR2, HPN | CTSK 160/4885CTSS 65/4885AAK1 2679/4885 |
| US-20070142301-A1 | Novel inhibitors of Hepatitis C virus NS3 protease | HAVCR2, RNASE1, SERPINB1 | CTSK 275/4885CTSS 103/4885AAK1 2246/4885 |
| US-20070021351-A1 | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor | PYGL, SERPINB1, PREP | CTSK 239/4885CTSS 366/4885AAK1 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.